Clinical Physiology of Circulation

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery

Study of miRNAs in patients with hypertrophic obstructive cardiomyopathy

Authors: A.G. Ibragimova, A.V. Zubko, Yu.A. Chudinovskikh, M.I. Berseneva, D.A. Malenkov, M.V. Eremeeva

A.N. Bakoulev Scientific Center for Cardiovascular Surgery of Russian Academy of Medical Sciences

E-mail: Сведения доступны для зарегистрированных пользователей.

Link: Clinical Physiology of Blood Circulaiton. 2014; (): -

Quote as: Ibragimova A.G., Zubko A.V., Chudinovskikh Yu.A., Berseneva M.I., Malenkov D.A., Eremeeva M.V. Study of miRNAs in patients with hypertrophic obstructive cardiomyopathy. Klinicheskaya Fiziologiya Krovoobrashcheniya. 2014; 1: 21-25.

Full text:  


Objective. This study was sought to explore the expression and role of miRNA in patients with hypertrophic obstructive cardiomyopathy.

Material and methods.
miRNA were quantified by real-time polymerase chain reactions in 16 patients with hypertrophic obstructive cardiomyopathy and 2 health donors (mean age 38,1±13,9). Endomyocardial biopsies were obtained from the intraventricular septum during the surgical myectomy.

Results. In patients with HOCM myocardium expression of anti-hypertrophic mir-1, mir-133a and mir-133b was increased, expression of pro-hypertrophic mir- 208b and mir-214 was significantly higher and expression of pro-hypertrophic mir-208a and mir-195 was decreased in comparison to normal myocardium. We used RNU19 as a control gene.

Our results may become a foundation for the identification of new targets for influence by means of antagomirs for prevention of heart hypertrophy and decrease of progressive course of the disease.


1. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281–97. 2. Condorelli G., Latronico M.V., Dorn G.W. 2nd. MicroRNAs in heart disease: putative novel therapeutic targets? Eur. Heart J. 2010; 31: 649–58. 3. Costa Martins P.A., Bourajjaj M., Gladka M., Kortland M., van Oort R.J., Pinto Y.M. et al. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation. 2008; 118: 1567–76. 4. Da Costa Martins P.A., De Windt L.J. MicroRNAs in control of cardiac hypertrophy. Cardiovascular Research. 2012; 93: 563–72. 5. Thum T., Catalucci D., Bauersachs J. MicroRNAs: novel regulators in cardiac development and disease. Cardiovascular Research. 2008; 79: 562–70. 6. Boštjančič E., Zidar N., Štajer D., Glavač D. MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated in human myocardial infarction. Cardiology. 2010; 115: 163–9. 7. Ding S.L., Zhou L.Y., Li P.F. MicroRNA in cardiac hypertrophy: angels or devils. WIREs RNA. 2011; 2: 124–32. 8. Wang J., Yang X. The function of miRNA in cardiac hypertrophy. Cell. Mol. Life Sci. 2012; 69: 3561–70.

 If you found mistakes, select text and press Alt+A